A phase I study of LJPC-1010 for the treatment of nonalcoholic steatohepatitis (NASH)

Trial Profile

A phase I study of LJPC-1010 for the treatment of nonalcoholic steatohepatitis (NASH)

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 07 May 2015

At a glance

  • Drugs LJPC 1010 (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Adverse reactions
  • Most Recent Events

    • 07 May 2015 According to a La Jolla Pharmaceutical Company media release, the company it will not proceed with this trial and will instead explore out-licensing opportunities for this product candidate.
    • 07 May 2015 Status changed from planning to withdrawn prior to enrolment, according to a La Jolla Pharmaceutical Company media release.
    • 29 Apr 2015 Planned initiation date changed from 1 Jan 2015 to 1 Sep 2015, as reported in a La Jolla Pharmaceutical Company media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top